MaxCyte, Inc. Director/PDMR Shareholding (9375V)

TIDMMXCT TIDMMXCR

RNS Number : 9375V

MaxCyte, Inc.

26 July 2018

MaxCyte, Inc.

("MaxCyte" or the "Company")

Person Closely Associated Dealing

Maryland, USA, 26 July 2018 - MaxCyte (LSE: MXCT, MXCR) the global cell-based medicines and technology company, announces that Karin Johnston, wife of John Johnston, Non-Executive Director of the Company, has bought 11,500 shares of common stock of 0.1 pence each in the capital of the Company ("Common Stock") at a price of 240 pence per Common Stock.

Following this purchase, John Johnston has a beneficial interest of 86,500 Common Stock, representing 0.2% of the issued share capital of the Company and a further 64,800 options over Common Stock.

NOTIFICATION AND PUBLIC DISCLOSURE OF TRANSACTIONS BY PERSONS DISCHARGING MANAGERIAL RESPONSIBILITIES AND PERSONS CLOSELY ASSOCIATED WITH THEM

 
 1     Details of the person discharging managerial responsibilities/person 
        closely associated 
 a)    Name                                    Karin Johnston 
      ======================================  ======================================== 
 2     Reason for the notification 
      ================================================================================ 
 a)    Position/status                         Person closely associated 
      ======================================  ======================================== 
 b)    Initial notification/Amendment          Initial notification 
      ======================================  ======================================== 
 3     Details of the issuer, emission allowance market participant, 
        auction platform, auctioneer or auction monitor 
      ================================================================================ 
 a)    Name                                    MaxCyte, Inc. 
      ======================================  ======================================== 
 b)    LEI                                     54930053YHXULRFCU991 
      ======================================  ======================================== 
 4     Details of the transaction(s): section to be repeated 
        for (i) each type of instrument; (ii) each type of transaction; 
        (iii) each date; and (iv) each place where transactions 
        have been conducted 
      ================================================================================ 
 a)    Description of                          Purchase of Common Stock 
        the financial 
        instrument, type 
        of instrument 
      ======================================  ======================================== 
 b)    Identification                          US57777K1060 
        Code 
      ======================================  ======================================== 
 c)    Nature of the                           Purchase of Common Stock by a person 
        transaction                             closely associated 
      ======================================  ======================================== 
 d)    Price(s) and volume(s)                  Price(s)                    Volume(s) 
      ======================================  ===========================  =========== 
        240.00 pence                                                       11,500 
  =======================================================================  =========== 
 e)    Aggregated information                  N/A (Single Transaction) 
   - Aggregated volume                     11,500 
   - Price                                 240.00 
 ======================================  ============================================= 
 f)    Date of the transaction                 26 July 2018 
      ======================================  ======================================== 
 g)    Place of the transaction                London Stock Exchange, AIM Market 
      ======================================  ======================================== 
 

For further information, please contact:

 
 MaxCyte Inc. 
 Doug Doerfler, Chief Executive Officer 
  Ron Holtz, Chief Financial Officer          [phone] 
 
   Nominated Adviser and Broker 
   Panmure Gordon 
 Emma Earl, Freddy Crossley, Ryan McCarthy 
  (Corporate Finance) 
  James Stearns (Corporate Broking)           [phone] 
 
   Financial PR Adviser 
   Consilium Strategic Communications 
 Mary-Jane Elliott                            [phone] 
  Chris Welsh                                  [e-mail] 
  Sukaina Virji 
 

About MaxCyte

MaxCyte is a global cell-based medicines and life sciences company applying its patented cell engineering technology to help patients with high unmet medical needs in a broad range of conditions. MaxCyte is developing novel CARMA therapies for its own pipeline. CARMA is MaxCyte's mRNA-based proprietary platform for autologous cell therapy. In addition, through its core business, the Company leverages its Flow Electroporation(R) Technology to enable its partners across the biopharmaceutical industry to advance the development of innovative medicines, particularly in cell therapy, including gene editing and immuno-oncology. The Company has placed its cutting-edge flow electroporation instruments worldwide, including with nine of the top 10 global biopharmaceutical companies, and has more than 55 partnered programme licenses in cell therapy including more than 25 licensed for clinical use. With its robust delivery technology, MaxCyte helps its partners to unlock the full potential of their products.

For more information, visit www.maxcyte.com

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [e-mail] or visit www.rns.com.

END

DSHEAKXKADAPEFF

(END) Dow Jones Newswires

July 26, 2018 12:33 ET (16:33 GMT)